Gt Biopharma Inc (GTBP)

$2.77

+0.01

(+0.18%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.72
    $2.80
    $2.77
    downward going graph

    1.81%

    Downside

    Day's Volatility :2.68%

    Upside

    0.89%

    downward going graph
  • $2.60
    $10.66
    $2.77
    downward going graph

    6.14%

    Downside

    52 Weeks Volatility :75.61%

    Upside

    74.02%

    downward going graph

Returns

PeriodGt Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
-17.49%
6.5%
0.0%
6 Months
-56.42%
7.1%
0.0%
1 Year
-68.38%
9.8%
0.0%
3 Years
-99.19%
14.2%
-20.2%

Highlights

Market Capitalization
5.9M
Book Value
$3.85
Earnings Per Share (EPS)
-7.01
Wall Street Target Price
150.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-54.18%
Return On Equity TTM
-104.94%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-6.8M
Diluted Eps TTM
-7.01
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-2.7
EPS Estimate Next Quarter
-2.7

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Gt Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 5315.16%

Current $2.77
Target $150.00

Technicals Summary

Sell

Neutral

Buy

Gt Biopharma Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gt Biopharma Inc
Gt Biopharma Inc
-9.06%
-56.42%
-68.38%
-99.19%
1273.13%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gt Biopharma Inc
Gt Biopharma Inc
NA
NA
NA
0.0
-1.05
-0.54
NA
3.85
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gt Biopharma Inc
Gt Biopharma Inc
Buy
$5.9M
1273.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Gt Biopharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 130.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 285.7%

Institutional Holdings

  • DekaBank Deutsche Girozentrale

    50.71%

  • Vanguard Group Inc

    0.95%

  • BMO Capital Markets Corp.

    0.92%

  • Bank of Montreal

    0.92%

  • Geode Capital Management, LLC

    0.52%

  • BlackRock Inc

    0.47%

Company Information

using our proprietary platform technology, gt biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary nk cell engager (trike) platform technology. (nasdaq: gtbp)

Organization
Gt Biopharma Inc
Employees
2
CEO
Mr. Michael Martin Breen
Industry
Pharmaceuticals: Other

Discover More

FAQs